Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | GPR3 | P46089 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL27658861 | 0.97 | SMN1; SMN2 (0.56) | SMN1; SMN2GPR3NPC1RAB9AALDH1A1 | |
| SCHEMBL17153810 | 0.84 | SMN1; SMN2 (0.47) | SMN1; SMN2GPR3NPC1RAB9AALDH1A1 | |
| SCHEMBL30451373 | 0.84 | KDM4E (0.71) | SMN1; SMN2GPR3NPC1RAB9AALDH1A1 | |
| SCHEMBL18544881 | 0.84 | SMN1; SMN2 (0.47) | SMN1; SMN2GPR3NPC1RAB9AALDH1A1 | |
| SCHEMBL29717228 | 0.84 | SMN1; SMN2 (0.47) | SMN1; SMN2GPR3NPC1RAB9AALDH1A1 | |
| SCHEMBL2306302 | 0.84 | MEN1 (0.50) | SMN1; SMN2GPR3NPC1RAB9AALDH1A1 | |
| SCHEMBL8273098 | 0.84 | SMN1; SMN2 (0.47) | SMN1; SMN2GPR3NPC1RAB9AALDH1A1 | |
| SCHEMBL7074741 | 0.84 | SMN1; SMN2 (0.47) | SMN1; SMN2GPR3NPC1RAB9AALDH1A1 | |
| SCHEMBL5385941 | 0.84 | SMN1; SMN2 (0.47) | SMN1; SMN2GPR3NPC1RAB9AALDH1A1 | |
| SCHEMBL30645164 | 0.84 | MEN1 (0.50) | SMN1; SMN2GPR3NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023066377-A1 | NITROGEN-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 索智生物科技（浙江）有限公司 | 2023-04-27 | — | — | WO | disclosed |
| WO-2022212819-A1 | INDAZOLE DERIVATIVES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY (US) | 2022-10-06 | — | — | WO | disclosed |
| WO-2022140499-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY (US) | 2022-06-30 | — | — | WO | disclosed |
| EP-1857521-B2 | ORGANIC ELECTRIC FIELD LIGHT EMITTING ELEMENT AND PRODUCTION THEREFOR | MITSUBISHI CHEM CORP (JP) | 2021-12-22 | — | — | EP | disclosed |
| EP-3500559-B1 | HETEROCYCLIC LIPOXIN ANALOGS AND USES THEROF | UNIV COLLEGE DUBLIN NAT UNIV IRELAND DUBLIN (IE) | 2021-06-16 | — | — | EP | disclosed |
| US-20200332193-A1 | LIQUID CRYSTAL ELEMENT USED FOR PHASE CONTROL OF ELECTROMAGNETIC WAVE SIGNAL | JNC CORPORATION (JP) | 2020-10-22 | — | — | US | disclosed |
| WO-2020007017-A1 | CHIRAL BISAMINO-ETHER COMPOUNDS, AND METHOD OF PREPARATION AND USE THEREOF | JINAN UNIVERSITY (CN) | 2020-01-09 | — | — | WO | disclosed |
| CN-110099898-A | compound and use thereof | 优曼尼蒂治疗公司 | 2019-08-06 | — | — | CN | disclosed |
| EP-2887964-B1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX INC (US) | 2019-07-03 | — | — | EP | disclosed |
| US-10249830-B2 | Carbazole-based compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2019-04-02 | — | — | US | disclosed |
| US-7223531-B2 | Photothermographic material | FUJIFILM CORPORATION (JP) | 2007-05-29 | — | — | US | disclosed |
| US-7202019-B2 | Photothermographic imaging material | KONICA MINOLTA HOLDINGS, INC. (JP) | 2007-04-10 | — | — | US | disclosed |
| US-7176312-B2 | Kinase inhibitor scaffolds and methods for their preparation | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-02-13 | — | — | US | disclosed |
| US-20070003884-A1 | Photothermographic material | FUJI PHOTO FILM CO., LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
| US-20070003884-A1 | Photothermographic material | FUJI PHOTO FILM CO., LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
| US-7115359-B2 | Photothermographic material | KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) | 2006-10-03 | — | — | US | disclosed |
| US-20050037298-A1 | Photothermographic material | KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-1500973-A2 | Photothermographic material | Konica Minolta Medical & Graphic, Inc. (JP) | 2005-01-26 | — | — | EP | disclosed |
| US-20040101794-A1 | Photothermographic imaging material | KONICA MINOLTA HOLDINGS, INC. (JP) | 2004-05-27 | — | — | US | disclosed |
| US-6207666-B1 | TREATING PRECANCEROUS LESIONS BY ADMINISTERING 4-PHENYLPHTHALAZINE DERIVATIVE | CELL PATHWAYS, INC. | 2001-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10249830-B2 | Carbazole-based compound and organic light-emitting device including the same | OCIAD1, OXA1L, OCIAD2 | SMN1; SMN2 3465/4885GPR3 907/4885NPC1 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.